ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
ASLAN Pharmaceuticals Limited - American Depositary Shares (ASLN)
US:NASDAQ Investor Relations:
ir.aslanpharma.com
Company Research
Source: GlobeNewswire
SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Dr Carl Firth, Chief Executive Officer is scheduled to make a company presentation on 16 September 2020 at 9:00am EDT. The virtual conference will be held from 14-16 September 2020. The presentation deck used at the conference will be available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event. Media and IR contacts Emma ThompsonSpurwing CommunicationsTel: +65 6751 2021Email: ASLAN@spurwingcomms.com Robert UhlWestwicke PartnersTel: +1 858 356 5932 Email: robert.uhl@westwicke.com About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology and oncology focused biopharmaceutical com
Show less
Read more
Impact Snapshot
Event Time:
ASLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASLN alerts
High impacting ASLAN Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASLN
News
- ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference [Yahoo! Finance]Yahoo! Finance
- ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International ConferenceGlobeNewswire
- ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients [Yahoo! Finance]Yahoo! Finance
- ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis PatientsGlobeNewswire
ASLN
Sec Filings
- 4/22/24 - Form 6-K
- 4/19/24 - Form 6-K
- 4/12/24 - Form 424B5
- ASLN's page on the SEC website